Member Posts > Cardiol Therapeutics: Transforming Lives with Innovative Heart Disease Therapies
For patients suffering from recurrent pericarditis and acute myocarditis, the lack of effective long-term treatments can lead to repeated hospitalizations, chronic pain, and a declining quality of life. Cardiol Therapeutics (NASDAQ: CRDL; TSX: CRDL) is working to change that with CardiolRx™, an oral cannabidiol-based therapy designed to reduce inflammation and fibrosis in the heart.
How CardiolRx™ is Making a Difference
💊 MAvERIC-Pilot Study Results (November 18, 2024)
• Patients experienced fewer recurrences of pericarditis.
• Symptom relief and improved mobility were reported within weeks.
• Reduced dependence on steroids and NSAIDs, lowering risks of side effects.
🏥 ARCHER Trial Progress (September 24, 2024)
• Studying CardiolRx™ for acute myocarditis, which disproportionately affects young adults.
• Potential to prevent heart failure progression, a major concern in myocarditis patients.
🚀 Path to FDA Approval & Expanded Access
• Late-stage trials are key to making CardiolRx™ widely available.
• Potential for compassionate use programs as more data emerges.
With a commitment to patient-centric innovation, Cardiol Therapeutics is leading the way in transforming cardiovascular care.

#Biotech #StockMarket #CardiolTherapeutics #NASDAQ #Healthcare #Pharma #Finance #MarketNews #HeartHealth #MedicalInnovation #Myocarditis #Pericarditis #CannabidiolResearch #CardiolRx #CRD38 #ClinicalTrials